Generic substitution of antiepileptic drugs - A survey of patients' perspectives in Germany and other German-speaking countries

Epilepsy and Behavior

Volumn 27, Issue 1, 2013, Pages 135-139

  Hensler, Katrin ^a   Uhlmann, Carmen ^b   Porschen, Thomas ^c   Benecke, Reiner ^a   Rösche, Johannes ^a  

^a ROSTOCK UNIVERSITY MEDICAL CENTER   (Germany)

^b Abteilung Psychiatrie und Psychotherapie des Kindes und Jugendalters   (Germany)

^c Landesverband für Epilepsie Selbsthilfe in Nordrhein Westfalen e V   (Germany)

Author keywords

Epilepsy; Generic antiepileptic drug; Patients' perspective

Indexed keywords

ANTICONVULSIVE AGENT;

ADULT; AGED; ARTICLE; CROSS-SECTIONAL STUDY; EPILEPSY; FEMALE; GERMANY; HEALTH SURVEY; HUMAN; INTERNET; MAJOR CLINICAL STUDY; MALE; QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; ANTICONVULSANTS; ATTITUDE; AUSTRIA; CROSS-SECTIONAL STUDIES; DRUG SUBSTITUTION; DRUGS, GENERIC; EPILEPSY; FEMALE; GERMANY; HEALTH SURVEYS; HUMANS; MALE; MIDDLE AGED; PATIENT PREFERENCE; QUESTIONNAIRES; SWITZERLAND; YOUNG ADULT;

EID: 84873981407     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2012.12.029     Document Type: Article

References (27)

1. Crawford P., Hall W.W., Chappell B., Collings J., Stewart A. Generic prescribing for epilepsy. Is it safe?. Seizure 1996, 5:1-5.
2. Guberman A., Corman C. Generic substitution for brand name antiepileptic drugs: a survey. Can J Neurol Sci 2000, 27:37-43.
3. Haskins L.S., Tomaszewski K.J., Crawford P. Patient and physician reactions to generic substitution in the treatment of epilepsy. Epilepsy Behav 2005, 7:98-105.
4. McAuley J.W., Chen A.Y., Elliot J.O., Shneker B.F. An assesment of patient and pharmacist knowledge of and attitudes toward reporting adverse drug events due to formulation switching in patients with epilepsy. Epilepsy Behav 2009, 14:113-117.
5. Papsdorf T.B., Ablah E., Ram S., Sadler T., Liow K. Patient perception of generic antiepileptic drugs in the Midwestern United States. Epilepsy Behav 2009, 14:150-153.
6. Yamada M., Welty T.E. Generic substitution of antiepileptic drugs: a systematic review of prospective and retrospective studies. Ann Pharmacother 2011, 45:1406-1415.
7. Andermann F., Duh M.S., Gosselin A., Paradis P.E. Compulsory generic switching of antiepileptic drugs: high switchback rates to branded compounds compared with other drug classes. Epilepsia 2007, 48:464-469.
8. LeLorier J., Duh M.S., Paradis P.E., et al. Clinical consequences of generic substitution of lamotrigine for patients with epilepsy. Neurology 2008, 70:2179-2186.
9. Helmers S.L., Paradis P.E., Manjunath R., et al. Economic burden associated with the use of generic antiepileptic drugs in the United States. Epilepsy Behav 2010, 18:437-444.
10. Labiner D.M., Paradis P.E., Manjunath R., et al. Generic antiepileptic drugs and associated medical resource utilization in the United States. Neurology 2010, 74:1566-1574.
11. Rösche J. Generika in der Epileptologie. Pharmakologische Problematik, klinische Risiken und subjektive Sorgen. Psychopharmakotherapie 2010, 17:227-233.
12. Pfäfflin M., May T., Stefan H., Adelmeier U. Epilepsiebedingte Beeinträchtigungen im täglichen Leben und in der Erwerbstätigkeit - Querschnittsstudie an Patienten niedergelassener Ärzte. Neurol Rehabil 2000, 6:140-148.
13. Hamer H.M., Dodel R., Strzelczyk A., et al. Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany - a nationwide population-based study in children and adults. J Neurol 2012, 10.1007/s00415-012-6509-3.
14. Food and Drug Administration Summary minutes of the Advisory Committee for Pharmceutical Science and Clinical Pharmacology [accessed 2012 Aug 16]. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/AdvisoryCommitteeforPharmaceuticalScienceandClinicalPharmacology/UCM272111.pdf.
15. Beyenburg S., Dennig D., Ebner A., et al. Erster epileptische Anfall und Epilepsien im Erwachsenenalter [accessed 2012 Aug 14]. http://www.dgn.org/inhalte-a-z/503-leitlinien-der-dgn-erster-epileptischer-anfall-und-epilepsien-imerwachsenenalter.html.
16. Makus K.G., McCormick J. Identification of adverse reactions that can occur on substitution of generic for branded lamotrigine in patients with epilepsy. Clin Ther 2007, 29:334-341.
17. Krauss G.L., Caffo B., Chang Y.-T., Hendrix C.W., Chuang K. Assessing bioequivalence of generic antiepileptic drugs. Ann Neurol 2011, 70:221-228.
18. Erickson S.C., Le L., Ramsey S.D., et al. Clinical and pharmacy utilization outcomes with brand to generic antiepileptic switches in patients with epilepsy. Epilepsia 2011, 52(7):1365-1371.
19. Aldenkamp A.P., Rentmeester T., Hulsman J., et al. Phamracokinetics and cognitive effects of carbamazepine formulations with different dissolution rates. Eur J Clin Pharmacol 1998, 54:185-192.
20. Chen S.S., AllenJ Oxley J., Richens A. Comparative bioavailability of phenytoin from generic formulations in the United Kingdom. Epilepsia 1982, 23:49-52.
21. Hartley R., Aleksandrowicz J., Ng P.C., McLain B., Bowmer C.J., Forsythe W.I. Breakthrough seizures with generic carbamazepine: a consequence of poorer bioavailability?. Br J Clin Pract 1990, 44:270-273.
22. Jumao-as A., Bella I., Craig B., Lowe J., Dasheiff R.M. Comparison of steady-state blood levels of two carbamazepine formulations. Epilepsia 1989, 30:67-70.
23. Oles K.S., Penry J.K., Smith L.D., Anderson R.L., Dean J.C., Riela A.R. Therapeutic bioequivalence study of brand name versus generic carbamazepine. Neurology 1992, 42:1147-1153.
24. Silpakit O., Amornpichetkoon M., Kaojarern S. Comparative study of bioavailability and clinical efficacy of carbamazepine in epileptic patients. Ann Pharmacother 1997, 54:185-192.
25. Duh M.S., Paradis P.E., Latrémouille-Viau D., et al. The risks and costs of multiple-generic substitution of topiramate. Neurology 2009, 72:2122-2129.
26. Rascati K.L., Richards K.M., Johnsrud M.T., Mann T.A. Effects of antiepileptic drug substitutions on epileptic events requiring acute care. Pharmacotherapy 2009, 29:769-774.
27. Zachry W.M., Doan Q.D., Clewell J.D., Smith B.J. Case-control analysis of ambulance, emergency room, or inpatient hospital events for epilepsy and antiepileptic drug formlation changes. Epilepsia 2009, 50:493-500.